NAGE

Niagen Bioscience, Inc. (NAGE) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended March 31, 2025. Niagen Bioscience, Inc. (formerly ChromaDex Corporation) is a global bioscience company focused on healthy aging, primarily through its proprietary NAD+ precursor, Niagen®. The company operates three segments: Consumer Products (Tru Niagen®), Ingredients (food and pharmaceutical-grade Niagen®), and Analytical Reference Standards and Services. As of May 5, 2025, there were 78,769,662 shares of common stock outstanding.

Key Financial Metrics

Note: The company has no outstanding borrowings under its line of credit. Total liabilities are $25.99 million, primarily consisting of accounts payable, accrued expenses, and lease obligations.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 38% year-over-year to $30.5 million. This was driven by a 24% increase in Consumer Products sales (primarily e-commerce) and a 100% increase in Ingredients sales, fueled by the launch of pharmaceutical-grade Niagen® ($1.0 million in sales) and higher food-grade ingredient demand.
• Profitability Turnaround: The company reported a net income of $5.1 million compared to a net loss of $0.5 million in Q1 2024. Operating income improved from a loss of $0.7 million to a profit of $4.8 million.
• Margin Expansion: Gross margin improved by 270 basis points to 63.4%, attributed to operational efficiency and favorable product mix shifts. Cost of sales as a percentage of net sales decreased from 39% to 37%.
• Cash Flow Improvement: Net cash provided by operating activities surged to $7.9 million from $0.3 million, driven by improved net income, higher collections on trade receivables, and a $1.3 million recovery of credit losses related to legal settlements.
• Expense Management: R&D expenses decreased 40% to $1.3 million as spending normalized following the launch of the Niagen Plus product line in the prior year. Sales and marketing expenses increased 20% to $8.1 million but improved as a percentage of sales.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management anticipates that current unrestricted cash ($55.5 million) and cash generated from operations will be sufficient to meet obligations for at least the next 12 months. However, the company may seek additional capital to fund long-term strategic objectives. The company continues to negotiate a long-term supply agreement with W.R. Grace, its sole supplier of NRC, currently operating under a rolling forecast obligating approximately $16.4 million in purchases through September 2025.

Legal Contingencies:

• Elysium Health Settlement: The company fully satisfied a $2.65 million settlement with Elysium Health in Q1 2025, recording the second installment as a recovery of credit losses.
• Delaware Patent Litigation: The company is appealing a district court ruling requiring it to pay Elysium approximately $9.2 million in fees and costs. Management believes the court abused its discretion. If the appeal fails, the company estimates a potential liability of approximately $10.4 million (including interest). No accrual has been recorded as the outcome is uncertain.

Risks: Key risks include reliance on a single supplier (W.R. Grace) for NRC, potential inability to raise additional capital on favorable terms, and the outcome of ongoing patent litigation. The company also faces regulatory risks regarding FDA oversight of pharmaceutical-grade Niagen® and FTC/FTC warning letters regarding past marketing claims.

Investor Verification Checklist

• Supplier Concentration: Verify the status of negotiations with W.R. Grace for a long-term supply agreement beyond the current rolling forecast.
• Legal Liability: Monitor the progress of the appeal regarding the $9.2 million fee award in the Delaware patent infringement case against Elysium Health.
• Pharmaceutical-Grade Growth: Assess the sustainability of the new pharmaceutical-grade Niagen® revenue stream ($1.0M in Q1) and the expansion of 503B outsourcing facility partnerships.
• Cash Burn vs. Generation: Confirm that operating cash flow remains positive and sufficient to cover the $16.4 million in near-term inventory purchase commitments without immediate dilution.
• Customer Concentration: Review the concentration of trade receivables, noting that 61.9% is held by three major customers (including A.S. Watson Group and Amazon).